{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-007217","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.178502+00:00","generated_at":"2026-06-05T12:12:04.685608+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zai Lab FY2023 product revenue $266.7M (+25% YoY); VYVGART launch drives 2024 outlook >$70M","bullets":["Product revenue $266.7M (+25% YoY; +31% CER); net loss narrowed to $334.6M from $443.3M.","VYVGART launched Sept 2023; 2023 revenue $10M; ~1,000 patients treated in Jan 2024; 2024 guidance >$70M.","ZEJULA $168.8M (+16% YoY); OPTUNE $47.0M (flat); QINLOCK $19.2M (+29%); NUZYRA $21.7M (+316%).","Cash $807.6M (Dec 31, 2023) vs $1.0B year prior; R&D down, SG&A up on VYVGART launch.","Targeting profitability by end of 2025; regulatory submissions expected for 4 new products in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-007217","json":"https://secwatch.observer/filing/0001628280-24-007217.json","markdown":"https://secwatch.observer/filing/0001628280-24-007217.md","text":"https://secwatch.observer/filing/0001628280-24-007217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000162828024007217/0001628280-24-007217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000162828024007217/zlab-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:12:04.685608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b539434929f2b2e7da45cdee14328f5cfd0e0094","claim":"Zai Lab Ltd reported the year ended December 31, 2023 results: revenue $266.7 million, net income $334.6 million, EPS loss per ordinary share attributable to common stockholders of $0.35 (or loss per American Deposit Share (\"ADS\") of $3.4.","evidence_excerpt":"by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates – Total product revenue of $266.7 million for Full-Year 2023, representing 25% y-o-y growth; 31% y-o-y growth at constant exchange rate (CER) – VYVGART ® (efgartigimod alfa injection) was launched in September 2023 in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704292/000162828024007217/0001628280-24-007217-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$266.7 million"},{"label":"Net income","value":"$334.6 million"},{"label":"EPS","value":"loss per ordinary share attributable to common stockholders of $0.35 (or loss per American Deposit Share (\"ADS\") of $3.4"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}